FMS' fourth-quarter results showcase a strong segmental performance along with providing full year 2025 outlook for revenue growth and operating...

TEM's fourth-quarter results reflect strong segmental performance. However, the company continues to incur losses at the operational level.

Box's fourth-quarter 2025 results reflect strong Suite adoption.

UTHR beats fourth-quarter estimates for both earnings and sales. Tyvaso sales fall short of estimates. Stock down in pre-market trading.

Catalyst stock gains on strong fourth-quarter results, beating earnings and revenue estimates, primarily driven by Firdapse sales.

Strength in Avanos' Digestive Health segment drives its fourth-quarter 2024 performance despite global macroeconomic challenges.

NGVT's top line declines year over year in the fourth quarter due to the repositioning of the Performance Chemicals segment.

Myriad Genetics achieves strong revenue growth in the fourth quarter of 2024.

Baxter reports better-than-expected fourth-quarter results. However, the company's gross and operating margins contract. Shares rise in pre-market.

PCRX reports mixed fourth-quarter 2024 results, wherein earnings beat estimates but revenues miss. Exparel sales witness year-over-year growth.